ChiCTR2000034059 版本V1.1 版本创建时间2020/06/22 04:34:23 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000034059 

最近更新日期:

Date of Last Refreshed on:

2020-06-22 04:33:36 

注册时间:

Date of Registration:

2020-06-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于肠道微生态系统的组学研究构建结直肠癌的早期预警系统

Public title:

Construction of an early warning system for colorectal cancer basing on the omics research of intestinal microecosystem

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于大数据分析和深度学习模型构建结直肠癌防治智能系统

Scientific title:

Construction of an intelligent system for prevention and treatment of colorectal cancer basing on big data analysis and deep learning model

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

韩书文 

研究负责人:

韩书文 

Applicant:

Han Shuwen 

Study leader:

Han Shuwen 

申请注册联系人电话:

Applicant telephone:

+86 0572 2555750

研究负责人电话:

Study leader's
telephone:

+86 0572 2555750

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

shuwenhan985@163.com

研究负责人电子邮件:

Study leader's E-mail:

shuwenhan985@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省湖州市红旗路198号

研究负责人通讯地址:

浙江省湖州市红旗路198号

Applicant address:

198 Hongqi Road, Huzhou, Zhejiang, China

Study leader's address:

198 Hongqi Road, Huzhou, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

湖州市中心医院

Applicant's institution:

Huzhou Central Hospital

研究负责人所在单位:

湖州市中心医院

Affiliation of the Leader:

Huzhou Central Hospital

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

湖州市中心医院

Primary sponsor:

Huzhou Central Hospital

研究实施负责(组长)单位地址:

浙江省湖州市红旗路198号

Primary sponsor's address:

198 Hongqi Road, Huzhou, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

中国

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

湖州市中心医院

具体地址:

浙江省湖州市红旗路198号

Institution
hospital:

Huzhou Central Hospital

Address:

198 Hongqi Road, Huzhou

经费或物资来源:

浙江省科技厅

Source(s) of funding:

Zhejiang Science and Technology Department Project

研究疾病:

结直肠癌  

Target disease:

Colorectal cancer

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

结直肠癌的早期预警系统以肠道微生态组学研究为基础,提高结直肠癌早期筛查水平,为结直肠癌高危人群提供早期预警。  

Objectives of Study:

A new diagnostic evaluation system was established basing on the study of intestinal microecoomics.It provides the basis for breaking the existing diagnostic evaluation system and realizing the accurate diagnosis of colorectal cancer.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)病理确诊为结直肠癌的患者;
(2)病理确诊为肠息肉患者;
(3)健康志愿者;
(4)本人或其代理人签署知情同意。

Inclusion criteria

(1)Patients diagnosed with colon cancer by transintestinal biopsy and pathology;
(2)Patients confirmed by intestinal polyp by transintestinal biopsy and pathology;
(3)healthy volunteers
(4)The self or his agent is signing the informed consent.

排除标准:

⑴合并有其他恶性肿瘤;⑵合并有严重心肺疾病;⑶患者入院前3个月有抗生素、激素或肠道菌群制剂使用史;⑷严重腹泻或便秘的患者。

Exclusion criteria:

(1)Patients with other malignant tumors;
(2)The patient has severe heart and lung disease;
(3)The patient had a history of using antibiotics, hormones or intestinal microflora preparations 3 months before admission
(4) Patients with severe diarrhea or constipation.

研究实施时间:

Study execute time:

From 2021-01-01 00:00:00 To 2023-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-01-01 00:00:00 To 2023-12-31 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

病理诊断

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Pathological diagnosis

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

基于肠道微生态系统的组学研究构建结直肠癌的早期预警系统

Index test:

基于肠道微生态系统的组学研究构建结直肠癌的早期预警系统

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

经病理诊断为结直肠癌患者

例数:

Sample size:

500

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Patients diagnosed as colorectal cancer by pathology

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

健康人群、肠息肉患者

例数:

Sample size:

500

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

Healthy people, patients with intestinal polyps

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

湖州市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Huzhou Central Hospital

Level of the institution:

Teriary A

测量指标:

Outcomes:

指标中文名:

肠道菌群

指标类型:

主要指标

Outcome:

Intestinal flora

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SEN, SPE, ACC

指标类型:

主要指标

Outcome:

SEN, SPE, ACC

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便标本

组织:

Sample Name:

stool samples

Tissue:

人体标本去向

使用后保存  

说明

3年

Fate of sample:

Preservation after use  

Note:

3 years

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Nonrandom grouping

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan, http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, http://www.medresman.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Resman

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Resman

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-06-22 04:32:09